Clariant has completed the sale of its Energy Storage business line, announced in October 2014, for $75 million to Johnson Matthey.
"The divestment of the Energy Storage business with its LFP technology is part of our focused portfolio management and reallocating capital towards our core areas Care Chemicals, Catalysis and Energy, Natural Resources and Plastics and Coatings," said CEO Hariolf Kottmann.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Ineos has completed a major £30 million investment at its Hull manufacturing site, converting the facility to run on clean-burning hydrogen instead of natural gas. This results in a 75% cut in carbon emissions.
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
